About Pricing FAQs Providers Trials Blog

Back to your record

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials in Pittsburgh | 245 Studies

Clinical Trials LymphomaPittsburgh

Lymphoma Clinical Trials in Pittsburgh

Find 245 clinical trials for lymphoma near Pittsburgh, Pennsylvania. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in Pittsburgh

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 161-180 of 245 trials

CompletedStudy of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's LymphomaThe purpose of this study is to determine if the combination of VELCADE and rituximab improves progression free survival relative to rituximab alone in patients with relapsed or…NCT00312845·Opelika, Alabama and 205 others

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedClinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell LymphomaThe Valchlor PROVe study is a multi-center, prospective, observational, US-based drug study that longitudinally follows patients with Mycosis Fungoides Cutaneous T-cell Lymphoma…NCT02296164·Little Rock, Arkansas and 35 others

CompletedRituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's LymphomaRATIONALE: Monoclonal antibodies, such as rituximab and galiximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.NCT00117975·Washington D.C., District of Columbia and 67 others

Active not recruitingA Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's LymphomaThis is a Phase I/II, multicenter, open-label, dose-escalation study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of a novel T-Cell bispecific…NCT03075696·Ann Arbor, Michigan and 33 others

CompletedSafety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2This is a multi-center phase Ib study, which evaluates the safety and efficacy of lacutamab monotherapy in patients with relapsed/refractory peripheral T-cell lymphoma that…NCT05321147·Birmingham, Alabama and 19 others

CompletedCampath-1H + FK506 and Methylprednisolone for GVHDRATIONALE: Alemtuzumab, tacrolimus, and methylprednisolone may be an effective treatment for graft-versus-host disease caused by a donor stem cell transplant.NCT00109993·New York, New York and 5 others

TerminatedStudy of XL114 in Subjects With Non-Hodgkin's LymphomaThis is a Phase 1, non-randomized, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and…NCT05144347·Tucson, Arizona and 3 others

CompletedA Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)To assess the efficacy, safety and pharmacokinetics in participants treated with CD11301 gel vs. placebo for early stage CTCL (IA, IB, or IIA).NCT03292406·Orange, California and 20 others

RecruitingSIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)This is a 3-part study.NCT05303519·Birmingham, Alabama and 60 others

RecruitingA Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma PatientsThis is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab…NCT06549595·Huntsville, Alabama and 243 others

CompletedImmunization Against Tumor Cells in Sezary SyndromeThis research is being done to look at the safety and value of a vaccine for a cancer found in the blood and skin known as Cutaneous T-cell lymphoma (CTCL) and Sezary Syndrome.NCT00099593·Pittsburgh, Pennsylvania

CompletedMORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or LymphomaThis phase I trial studies the side effects and best dose of MORAb-004 in treating young patients with recurrent or refractory solid tumors or lymphoma.NCT01748721·Birmingham, Alabama and 19 others

CompletedMultiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)This is a multi-center, randomized, placebo controlled, interventional phase 2A trial to evaluate the safety profile and potential efficacy of multi-dosing of mesenchymal stromal…NCT04466098·Minneapolis, Minnesota and 1 other

CompletedCombination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's LymphomaRATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.NCT00032019·Anniston, Alabama and 80 others

TerminatedTopotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid TumorsRATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.NCT00112619·San Francisco, California and 10 others

CompletedStudy To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic DermatitisStudy B7451006 is a Phase 2b POC study which is planned to assess four PF 04965842 once daily (QD) doses (10, 30, 100, 200 mg) relative to placebo over 12 weeks to characterize…NCT02780167·Birmingham, Alabama and 63 others

Active not recruitingEnsartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)This phase II Pediatric MATCH treatment trial studies how well ensartinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK or…NCT03213652·Birmingham, Alabama and 125 others

TerminatedStudy of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)This study evaluated the safety and efficacy of LBH589B in adult participants with refractory/resistant Cutaneous T-Cell Lymphoma and prior Histone Deacetylase (HDAC) inhibitor…NCT00490776·Birmingham, Alabama and 17 others

CompletedDepsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell LymphomaBackground: NSC630176 is a depsipeptide fermentation product from Chromobacterium violaceum with potent cytotoxic activity against human tumor cell lines and in vivo efficacy…NCT00007345·Scottsdale, Arizona and 12 others

CompletedA Study of Revlimid in the Treatment of Non-Hodgkin's LymphomaSubjects who qualify will receive oral lenalidomide daily on days 1-21 of every 28 day cycle.NCT00413036·Muscle Shoals, Alabama and 52 others

PreviousPage 9 of 13Next

Other Conditions in Pittsburgh

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia